根据美国药物信息协会(DIA)的全球执行董事Paul Pomerantz的回答,我写了一篇很扯的人物对话稿。

Q: what do you think of the first DIA China annual meeting? How do you rate it given the 100 points scale? What’s your impression to China?
A:The first DIA China annual meeting was a total success. 100 on a scale of 100. The meeting enjoyed support at the highest levels of the SFDA and gained worldwide recognition thought the participation of regulators internationally including those from the FDA, EMEA and PMDA. We believe China is a significant player in size and influence in both drug development and discovery. I have been very impressed by the enthusiasm of both government and industry leaders. China has a clear commitment to innovation, quality and leadership in the development of pharmaceutical and related products.
Q: Could you share with us your career story? what’s your best achievements till now? Is there any experience that can be taken as a turning point for your life?
A:My professional degree is in healthcare administration. I have worked in government, health care delivery (as a hospital administrator) and as a health care association executive. As an association executive, I have led international organizations serving clinical laboratory, radiology, plastic surgery and now pharmaceutical and medical product executives. There were three major professional turning points for me. My first “turning point” came in 1990 when I first became an association leader and learned of the tremendous impact associations can have on motivating and educating professionals. The second was in 1997 when the organization I was working with (Clinical Laboratory Management Association) succeeded in advancing legislation mandating an Institute of Medicine Study on laboratory payment. This affirmed for me the power of associations to develop public policy. The third came in my position with the Society of Interventional Radiology, when we were approached by the FDA to coordinate a post market study with several manufacturers involving a specific device. This milestone, which is often cited by the FDA as a model of private-public partnership, conveyed to me the power of collaboration and science. The study, which was very successful, was overseen by a steering group consisting of radiologists, consumers, FDA, industry representatives and health service researchers.
Q:In the past years, is there anyone or anything that brings a major influence to your life?
A:I feel many have influenced me as mentors or as role models. There have been some bosses, early in my career, who taught me the importance of vision and setting high standards, treating people well, hard work, leading teams to develop creative solutions to complex problems and execute projects, and concern for the patient and customer.
Q: Why did you join in DIA? Currently, what’s your focus and challenge in your work? What’s your expectation to yourself?
A:I was attracted by DIA’s mission, excited by our vision, and impressed by all the DIA leaders and members I met. The global nature of pharmaceutical (and related product) development and regulation, and the global challenge of health care costs, public health concerns (including pandemics, neglected diseases, and those of developing and developed nations) represent opportunities that can be best addressed through DIA’s neutral, multi-disciplinary stakeholder forum. I think DIA can truly make a difference to improve health care delivery and health status world wide.
My major focus at this time is aligning the organization to function more effectively as a global organization, to upgrade our technology to support our members around the world, to build awareness of DIA by those who might not be familiar with us, and to update our offerings consistent with changes in the health system.
Q: You once said, “drug is not only making medicines”, when you were elected to be the president of DIA, could you share your points of drug development? How to meet the unmet clinical needs with patient oriented?
A:Two key points: First, our world has expanded from drugs to “life sciences” and includes a range of regulated medical products that range from drugs, to biologics and bio-similars, to diagnostics and personalized medicine. Second, regulators in many countries, and thus companies, have expanded their focus from product approvals to post approval aspects including safety, technology assessment, and pricing. As a result, information technology, particularly electronic medical records and registries are playing an increasing role in DIA’s programs.
DIA has four key pillars: industry, regulators, academia, and to an increasing degree, patients. These are represented in many DIA regions by patient organization representatives who participate as part of governance (helping set direction) and in programs. At DIA, as for the industry and the regulators, the voice of the patient is becoming increasingly important. Their key concerns include innovation to treat neglected diseases, improvements to current treatment and safety.
Q: Last year, DIA set up its office in China, what’s your strategy here in China? What’s your expectation to China market given its unique healthcare system and pharmaceutical industry?
A:D